Protara TherapeuticsTARA
TARA
About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Employees: 33
0
Funds holding %
of 7,302 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
363% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $478K
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2% less funds holding
Funds holding: 60 [Q4 2024] → 59 (-1) [Q1 2025]
8.24% less ownership
Funds ownership: 86.45% [Q4 2024] → 78.22% (-8.24%) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
21% less capital invested
Capital invested by funds: $157M [Q4 2024] → $124M (-$32.8M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
293%
upside
Avg. target
$18.67
512%
upside
High target
$23
654%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Jones Trading Soumit Roy | 589%upside $21 | Buy Initiated | 22 May 2025 |
HC Wainwright & Co. Andres Maldonado | 654%upside $23 | Buy Reiterated | 28 Apr 2025 |
Scotiabank George Farmer | 293%upside $12 | Sector Outperform Initiated | 16 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara.
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to six newly-hired employees.
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ, or CIS (± Ta/T1), who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve. The results will be featured today during an interactive poster session at the American Urological Association 2025 Annual Meeting in Las Vegas.
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2025, at 7:00 a.m. PT.
Neutral
GlobeNewsWire
2 months ago
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies.
Neutral
GlobeNewsWire
2 months ago
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured at the upcoming American Urological Association (AUA) 2025 Annual Meeting taking place from April 26, 2025 to April 29, 2025 in Las Vegas.
Positive
Zacks Investment Research
2 months ago
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Seeking Alpha
2 months ago
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
TARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA's pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives.
Charts implemented using Lightweight Charts™